As Biotechnology company, Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) is competing with its competitors based on the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Insider and Institutional Ownership

Sienna Biopharmaceuticals Inc. has 32.3% of its shares held by institutional investors & an average of 52.39% institutional ownership for its rivals. 4.3% of Sienna Biopharmaceuticals Inc. shares are held by company insiders. Comparatively, 8.89% of all Biotechnology companies shares are held by company insiders.

Profitability

Table 1 has Sienna Biopharmaceuticals Inc. and its rivals’ return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals Inc.	0.00%	-97.50%	-50.20%
Industry Average	468.58%	80.16%	25.47%

Earnings and Valuation

The following data compares Sienna Biopharmaceuticals Inc. and its rivals’ valuation, gross revenue and net income.

	Net Income	Gross Revenue	Price/Earnings Ratio
Sienna Biopharmaceuticals Inc.	73.47M	N/A	0.00
Industry Average	14.75M	3.15M	89.01

Analyst Ratings

Table 3 shows summary of recent ratings for Sienna Biopharmaceuticals Inc. and its rivals.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Sienna Biopharmaceuticals Inc.	0	0	1	3.00
Industry Average	1.22	1.87	2.93	2.79

With average target price of $17, Sienna Biopharmaceuticals Inc. has a potential upside of 665.77%. As a group, Biotechnology companies have a potential upside of 126.19%. Given Sienna Biopharmaceuticals Inc.’s rivals higher probable upside, analysts plainly believe Sienna Biopharmaceuticals Inc. has less favorable growth aspects than its rivals.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Sienna Biopharmaceuticals Inc. and its rivals.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Sienna Biopharmaceuticals Inc.	13.44%	7.09%	-71.81%	-83.09%	-82.01%	23.71%
Industry Average	7.88%	20.03%	31.47%	42.06%	73.21%	38.48%

For the past year Sienna Biopharmaceuticals Inc. was less bullish than its competitors.

Liquidity

The Current Ratio and a Quick Ratio of Sienna Biopharmaceuticals Inc. are 4.9 and 4.9. Competitively, Sienna Biopharmaceuticals Inc.’s rivals have 7.48 and 7.37 for Current and Quick Ratio. Sienna Biopharmaceuticals Inc.’s peers have better ability to pay short and long-term obligations than Sienna Biopharmaceuticals Inc.

Dividends

Sienna Biopharmaceuticals Inc. does not pay a dividend.

Summary

Sienna Biopharmaceuticals Inc.’s peers beat Sienna Biopharmaceuticals Inc. on 3 of the 4 factors.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.